Therapeutics and Innovations in Psoriatic Arthritis

This chapter explores recent findings on bimikizumab and secukinamab as key therapeutic options for psoriatic arthritis presented at the ACR 2024 meeting. It discusses efficacy studies, safety data, and treatment response predictors, including JAK and TIK2 inhibitors, while delving into the broader context of rheumatoid arthritis management.